IBDEI0FT ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7615,0)
 ;;=363.70^^49^559^4
 ;;^UTILITY(U,$J,358.3,7615,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7615,1,3,0)
 ;;=3^Choroidal Detachment NOS
 ;;^UTILITY(U,$J,358.3,7615,1,4,0)
 ;;=4^363.70
 ;;^UTILITY(U,$J,358.3,7615,2)
 ;;=^276841
 ;;^UTILITY(U,$J,358.3,7616,0)
 ;;=365.24^^49^559^28
 ;;^UTILITY(U,$J,358.3,7616,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7616,1,3,0)
 ;;=3^Glaucoma,Residual Angle Closure
 ;;^UTILITY(U,$J,358.3,7616,1,4,0)
 ;;=4^365.24
 ;;^UTILITY(U,$J,358.3,7616,2)
 ;;=^268758
 ;;^UTILITY(U,$J,358.3,7617,0)
 ;;=365.65^^49^559^34
 ;;^UTILITY(U,$J,358.3,7617,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7617,1,3,0)
 ;;=3^Glaucoma,Traumatic
 ;;^UTILITY(U,$J,358.3,7617,1,4,0)
 ;;=4^365.65
 ;;^UTILITY(U,$J,358.3,7617,2)
 ;;=^268780
 ;;^UTILITY(U,$J,358.3,7618,0)
 ;;=365.89^^49^559^23
 ;;^UTILITY(U,$J,358.3,7618,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7618,1,3,0)
 ;;=3^Glaucoma,Oth Specified
 ;;^UTILITY(U,$J,358.3,7618,1,4,0)
 ;;=4^365.89
 ;;^UTILITY(U,$J,358.3,7618,2)
 ;;=^88069
 ;;^UTILITY(U,$J,358.3,7619,0)
 ;;=365.05^^49^559^38
 ;;^UTILITY(U,$J,358.3,7619,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7619,1,3,0)
 ;;=3^Opn Ang w/ brdrlne fnd-Hi Risk
 ;;^UTILITY(U,$J,358.3,7619,1,4,0)
 ;;=4^365.05
 ;;^UTILITY(U,$J,358.3,7619,2)
 ;;=^340511
 ;;^UTILITY(U,$J,358.3,7620,0)
 ;;=365.06^^49^559^40
 ;;^UTILITY(U,$J,358.3,7620,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7620,1,3,0)
 ;;=3^Prim Ang Clos w/o Glauc Dmg
 ;;^UTILITY(U,$J,358.3,7620,1,4,0)
 ;;=4^365.06
 ;;^UTILITY(U,$J,358.3,7620,2)
 ;;=^340512
 ;;^UTILITY(U,$J,358.3,7621,0)
 ;;=365.70^^49^559^31
 ;;^UTILITY(U,$J,358.3,7621,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7621,1,3,0)
 ;;=3^Glaucoma,Stage NOS
 ;;^UTILITY(U,$J,358.3,7621,1,4,0)
 ;;=4^365.70
 ;;^UTILITY(U,$J,358.3,7621,2)
 ;;=^340609
 ;;^UTILITY(U,$J,358.3,7622,0)
 ;;=365.71^^49^559^17
 ;;^UTILITY(U,$J,358.3,7622,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7622,1,3,0)
 ;;=3^Glaucoma,Mild Stage
 ;;^UTILITY(U,$J,358.3,7622,1,4,0)
 ;;=4^365.71
 ;;^UTILITY(U,$J,358.3,7622,2)
 ;;=^340513
 ;;^UTILITY(U,$J,358.3,7623,0)
 ;;=365.72^^49^559^18
 ;;^UTILITY(U,$J,358.3,7623,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7623,1,3,0)
 ;;=3^Glaucoma,Moderate Stage
 ;;^UTILITY(U,$J,358.3,7623,1,4,0)
 ;;=4^365.72
 ;;^UTILITY(U,$J,358.3,7623,2)
 ;;=^340514
 ;;^UTILITY(U,$J,358.3,7624,0)
 ;;=365.73^^49^559^30
 ;;^UTILITY(U,$J,358.3,7624,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7624,1,3,0)
 ;;=3^Glaucoma,Severe Stage
 ;;^UTILITY(U,$J,358.3,7624,1,4,0)
 ;;=4^365.73
 ;;^UTILITY(U,$J,358.3,7624,2)
 ;;=^340515
 ;;^UTILITY(U,$J,358.3,7625,0)
 ;;=365.74^^49^559^14
 ;;^UTILITY(U,$J,358.3,7625,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7625,1,3,0)
 ;;=3^Glaucoma,Indeterm Stage
 ;;^UTILITY(U,$J,358.3,7625,1,4,0)
 ;;=4^365.74
 ;;^UTILITY(U,$J,358.3,7625,2)
 ;;=^340516
 ;;^UTILITY(U,$J,358.3,7626,0)
 ;;=V19.11^^49^559^5
 ;;^UTILITY(U,$J,358.3,7626,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7626,1,3,0)
 ;;=3^Family Hx Glaucoma
 ;;^UTILITY(U,$J,358.3,7626,1,4,0)
 ;;=4^V19.11
 ;;^UTILITY(U,$J,358.3,7626,2)
 ;;=^340617
 ;;^UTILITY(U,$J,358.3,7627,0)
 ;;=V19.19^^49^559^6
 ;;^UTILITY(U,$J,358.3,7627,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7627,1,3,0)
 ;;=3^Family Hx Oth Spec Eye Disord
 ;;^UTILITY(U,$J,358.3,7627,1,4,0)
 ;;=4^V19.19
 ;;^UTILITY(U,$J,358.3,7627,2)
 ;;=^340618
 ;;^UTILITY(U,$J,358.3,7628,0)
 ;;=365.62^^49^559^8
 ;;^UTILITY(U,$J,358.3,7628,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7628,1,3,0)
 ;;=3^Glauc Assoc w/ Ocular Inflamm
 ;;^UTILITY(U,$J,358.3,7628,1,4,0)
 ;;=4^365.62
